Allied Healthcare Products (AHPIQ) 10-K 26 Sep 14 2014 FY Annual report Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
	Jun. 30, 2014	Sep. 05, 2014	Dec. 31, 2013
Document Information [Line Items]	'	'	'
Entity Registrant Name	'ALLIED HEALTHCARE PRODUCTS INC	'	'
Entity Central Index Key	'0000874710	'	'
Current Fiscal Year End Date	'--06-30	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Trading Symbol	'AHPI	'	'
Entity Common Stock, Shares Outstanding	'	8,027,147	'
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	30-Jun-14	'	'
Document Fiscal Period Focus	'FY	'	'
Document Fiscal Year Focus	'2014	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Voluntary Filers	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Public Float	'	'	$10,181,924

STATEMENT_OF_OPERATIONS

STATEMENT OF OPERATIONS (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Net sales	$36,370,616	$38,551,774	$43,445,621
Cost of sales	29,056,367	30,309,484	33,484,512
Gross profit	7,314,249	8,242,290	9,961,109
Selling, general and administrative expenses	10,423,133	10,735,806	10,610,858
Loss from operations	-3,108,884	-2,493,516	-649,749
Other (income) expenses:	'	'	'
Interest income	-4,818	-12,006	-27,368
Interest expense	0	0	336
Other, net	41,660	-484,699	47,629
Nonoperating income (expense)	36,842	-496,705	20,597
Loss before benefit from income taxes	-3,145,726	-1,996,811	-670,346
Benefit from income taxes	-339,813	-740,038	-245,920
Net loss	($2,805,913)	($1,256,773)	($424,426)
Basic loss per share (in dollars per share)	($0.35)	($0.16)	($0.05)
Diluted loss per share (in dollars per share)	($0.35)	($0.16)	($0.05)
Weighted average shares outstanding - Basic (in shares)	8,027,147	8,070,645	8,124,386
Weighted average shares outstanding - Diluted (in shares)	8,027,147	8,070,645	8,124,386

BALANCE_SHEET

BALANCE SHEET (USD $)	Jun. 30, 2014	Jun. 30, 2013
Current assets:	'	'
Cash and cash equivalents	$1,366,762	$3,687,919
Accounts receivable, net of allowances of $170,000	3,713,105	4,221,970
Inventory, Net	9,406,098	9,338,343
Income tax receivable	17,166	36,766
Other current assets	410,098	420,978
Total current assets	14,913,229	17,705,976
Property, plant and equipment, net	8,935,601	9,722,344
Deferred income taxes	1,996,434	1,667,699
Other assets, net	187,163	242,712
Total assets	26,032,427	29,338,731
Current liabilities:	'	'
Accounts payable	1,068,222	1,317,202
Other accrued liabilities	1,624,186	1,861,241
Deferred income taxes	830,946	845,539
Total current liabilities	3,523,354	4,023,982
Commitments and contingencies (Notes 4 and 10)	'	'
Stockholders' equity:	'	'
Preferred stock; $0.01 par value; 1,500,000 shares authorized; no shares issued and outstanding	0	0
Common stock; $0.01 par value; 30,000,000 shares authorized; 10,427,878 shares issued at June 30, 2014 and June 30, 2013; 8,027,147 shares outstanding at June 30, 2014 and June 30, 2013	104,279	104,279
Additional paid-in capital	48,585,236	48,584,999
Accumulated deficit	-5,199,654	-2,393,741
Less: treasury stock, at cost; 2,400,731 shares at June 30, 2014 and 2013	-20,980,788	-20,980,788
Total stockholders' equity	22,509,073	25,314,749
Total liabilities and stockholders' equity	26,032,427	29,338,731
Series A Preferred Stock [Member]	'	'
Stockholders' equity:	'	'
Preferred stock; $0.01 par value; 1,500,000 shares authorized; no shares issued and outstanding	$0	$0

BALANCE_SHEET_Parenthetical

BALANCE SHEET [Parenthetical] (USD $)	Jun. 30, 2014	Jun. 30, 2013
Allowances for accounts receivable (in dollars)	$170,000	$170,000
Preferred stock, par value (in dollars per share)	$0.01	$0.01
Preferred stock, shares authorized	1,500,000	1,500,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$0.01	$0.01
Common stock, shares authorized	30,000,000	30,000,000
Common stock, shares issued	10,427,878	10,427,878
Common stock, shares outstanding	8,027,147	8,027,147
Treasury stock, at cost	2,400,731	2,400,731
Series A Preferred Stock [Member]	'	'
Preferred stock, par value (in dollars per share)	$0.01	$0.01
Preferred stock, shares authorized	200,000	200,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

STATEMENT_OF_CHANGES_IN_STOCKH

STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (USD $)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Treasury Stock [Member]
Balance at Jun. 30, 2011	$27,159,412	$104,279	$48,499,103	($712,542)	($20,731,428)
Stock based compensation	41,699	0	41,699	0	0
Net loss for the year	-424,426	0	0	-424,426	0
Balance at Jun. 30, 2012	26,776,685	104,279	48,540,802	-1,136,968	-20,731,428
Stock based compensation	44,197	0	44,197	0	0
Net loss for the year	-1,256,773	0	0	-1,256,773	0
Purchases of treasury stock	-249,360	0	0	0	-249,360
Balance at Jun. 30, 2013	25,314,749	104,279	48,584,999	-2,393,741	-20,980,788
Stock based compensation	9,655	0	9,655	0	0
Net loss for the year	-2,805,913	0	0	-2,805,913	0
Reversal of deferred tax provision, stock options forfeited	-9,418	0	-9,418	0	0
Balance at Jun. 30, 2014	$22,509,073	$104,279	$48,585,236	($5,199,654)	($20,980,788)

STATEMENT_OF_CASH_FLOWS

STATEMENT OF CASH FLOWS (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Cash flows from operating activities:	'	'	'
Net loss	($2,805,913)	($1,256,773)	($424,426)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:	'	'	'
Depreciation and amortization	1,280,796	1,306,044	1,283,349
Stock based compensation	9,655	44,197	44,179
Provision for doubtful accounts and sales returns and allowances	18,852	10,372	27,025
Deferred tax benefit	-352,746	-757,699	-257,501
Changes in operating assets and liabilities:	'	'	'
Accounts receivable	490,013	741,251	446,242
Inventories	-67,755	662,883	552,063
Income tax receivable	19,600	9,276	49,536
Other current assets	10,880	-20,301	-186,932
Other assets, net	0	0	-275,000
Accounts payable	-248,980	-479,942	152,234
Deferred revenue	0	-114,700	-688,200
Other accrued liabilities	-237,055	-124,338	260,027
Net cash provided by (used in) operating activities	-1,882,653	20,270	982,596
Cash flows from investing activities:	'	'	'
Capital expenditures	-438,504	-1,367,534	-2,210,940
Net cash used in investing activities	-438,504	-1,367,534	-2,210,940
Cash flows from financing activities:	'	'	'
Purchases of treasury stock	0	-249,360	0
Net cash used in financing activities	0	-249,360	0
Net decrease in cash and cash equivalents	-2,321,157	-1,596,624	-1,228,344
Cash and cash equivalents at beginning of year	3,687,919	5,284,543	6,512,887
Cash and cash equivalents at end of year	1,366,762	3,687,919	5,284,543
Supplemental disclosures of cash flow information:	'	'	'
Cash paid during the year for: Interest	0	0	336
Cash paid during the year for: Income taxes	17,999	1,450	25,266
Non-cash investing and financing activity	'	'	'
Deferred tax provision on stock options forfeited and reclassified to additional paid in capital	$9,418	$0	$0

Organization

Organization	12 Months Ended
	Jun. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	'
		1	Organization
	Allied Healthcare Products, Inc. (the “Company” or “Allied”) is a manufacturer of respiratory products used in the health care industry in a wide range of hospital and alternate site settings, including post-acute care facilities, home health care and trauma care. The Company's product lines include respiratory care products, medical gas equipment and emergency medical products.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Significant Accounting Policies [Text Block]	'
		2	Summary of Significant Accounting Policies
	The significant accounting policies followed by Allied are described below.
	Use of estimates
	The policies utilized by the Company in the preparation of the financial statements conform to accounting principles generally accepted in the United States of America, and require management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual amounts could differ from those estimates.
	Revenue recognition
	Revenue is recognized for all sales, including sales to agents and distributors, at the time products are shipped and title has transferred, provided that a purchase order has been received or a contract executed, there are not uncertainties regarding customer acceptance, the sales price is fixed and determinable and collectability is reasonably assured. Sales discounts, returns and allowances are included in net sales, and the provision for doubtful accounts is included in selling, general and administrative expenses. Additionally, it is the Company’s practice to include revenues generated from freight billed to customers in net sales with corresponding freight expense included in cost of sales in the Statement of Operations. The Company reports sales taxes on sales transactions on a net basis in the Statement of Operations, and therefore does not include sales taxes in revenues or costs.
	The sales price is fixed by Allied’s acceptance of the buyer’s firm purchase order. The sales price is not contingent, or subject to additional discounts. Allied’s standard shipment terms are “F.O.B. shipping point” as stated in Allied’s Terms and Conditions of Sale. The customer is responsible for obtaining insurance for and bears the risk of loss for product in-transit. Additionally, sales to customers do not include the right to return merchandise without the prior consent of Allied. In those cases where returns are accepted, product must be current and restocking fees must be paid by the respective customer. A provision has been made for estimated sales returns and allowances. These estimates are based on historical analysis of credit memo data and returns.
	Allied does not provide installation services for its products. Most products shipped are ready for immediate use by the customer. The Company’s in-wall medical system components, central station pumps and compressors, and headwalls do require installation by the customer. These products are typically purchased by a third-party contractor who is ultimately responsible for installation services. Accordingly, the customer purchase order or contract does not require customer acceptance of the installation prior to completion of the sale transaction and revenue recognition. Allied’s standard payment terms are net 30 days from the date of shipment, and payment is specifically not subject to customer inspection or acceptance, as stated in Allied’s Terms and Conditions of Sale. The buyer becomes obligated to pay Allied at the time of shipment. Allied requires credit applications from its customers and performs credit reviews to determine the creditworthiness of new customers. Allied requires letters of credit, where warranted, for international transactions. Allied also protects its legal rights under mechanics lien laws when selling to contractors.
	Allied does offer limited warranties on its products.  The standard warranty period is one year.  The Company’s cost of providing warranty service for its products for the years ended June 30, 2014, 2013, and 2012 was $113,209, $150,944, and $152,625, respectively.  The related liability for warranty service amounted to $130,000 at June 30, 2014 and 2013.
	Marketing and Advertising Costs
	Promotional and advertising costs are expensed as incurred and are included in selling, general and administrative expenses in the Statement of Operations. Advertising expenses for the years ended June 30, 2014, 2013 and 2012 were $17,904, $46,691, and $46,278, respectively.
	Cash and cash equivalents
	For purposes of the statement of cash flows, the Company considers all highly liquid investments with a maturity of three months or less when acquired to be cash equivalents.
	The Company maintains funds in bank accounts that, at times, may exceed the limit insured by the Federal Deposit Insurance Corporation. The risk of loss attributable to these uninsured balances is mitigated by depositing funds only in high credit quality financial institutions. The Company has not experienced any losses in such accounts.
	Foreign currency transactions
	Allied has international sales which are denominated in U.S. dollars, the functional currency for these transactions.
	Accounts receivable and concentrations of credit risk
	Accounts receivable are recorded at the invoiced amount. The Company performs ongoing credit evaluations of its customers and generally does not require collateral. The Company maintains reserves for potential credit losses based on past experience and an analysis of current amounts due, and historically such losses have been within management's expectations. The Company maintains an allowance for doubtful accounts to reflect the uncollectibility of accounts receivable based on past collection history and specific risks indentified among uncollected accounts. Accounts receivable are charged to the allowance for doubtful accounts when the Company determines that the receivable will not be collected and/or when the account has been referred to a third party collection agency. The Company’s customers can be grouped into three main categories: medical equipment distributors, construction contractors and health care institutions. At June 30, 2014, the Company believes that it has no significant concentration of credit risk.
	Inventories
	Inventories are stated at the lower of cost, determined using the last-in, first-out (“LIFO”) method, or market. If the first-in, first-out method (which approximates replacement cost) had been used in determining cost, inventories would have been $2,473,787 and $2,343,788 higher at June 30, 2014 and 2013, respectively. Changes in the LIFO reserve are included in cost of sales. Cost of sales was reduced by $0, $171,918, and $164,645 in fiscal 2014, 2013, and 2012 respectively, as a result of LIFO liquidations. Costs in inventory include raw materials, direct labor and manufacturing overhead.
	Inventory is recorded net of a reserve for obsolete and excess inventory which is determined based on an analysis of inventory items with no usage in the preceding year and for inventory items for which there is greater than two years’ usage on hand. The reserve for obsolete and excess inventory was $1,433,718 and $1,312,600 at June 30, 2014 and 2013, respectively.
	Property, plant and equipment
	Property, plant and equipment are recorded at cost and are depreciated using the straight-line method over the estimated useful lives of the assets, which range from 3 to 35 years. Expenditures for repairs, maintenance and renewals are charged to income as incurred. Expenditures, which improve an asset or extend its estimated useful life, are capitalized. When properties are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the accounts and any gain or loss is included in income.
	Impairment of long-lived assets
	The Company evaluates impairment of long-lived assets under the provisions of ASC Topic 360: “Property, Plant and Equipment.” ASC 360 provides a single accounting model for long-lived assets to be disposed of and reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. Under ASC 360, if the sum of the expected future cash flows (undiscounted and without interest charges) of the long-lived assets is less than the carrying amount of such assets, an impairment loss will be recognized. No impairment losses of long-lived assets or identifiable intangibles were recorded by the Company for fiscal years ended June 30, 2014, 2013, and 2012.
	Collective Bargaining Agreement
	At June 30, 2014, the Company had approximately 243 full-time employees. Approximately 148 employees in the Company’s principal manufacturing facility located in St. Louis, Missouri, are covered by a collective bargaining agreement that will expire on May 31, 2015.
	Self-insurance
	The Company maintains a self-insurance program for a portion of its health care costs. Self-insurance costs are accrued based upon the aggregate of the liability for reported claims and the estimated liability for claims incurred but not reported. As of June 30, 2014 and 2013, the Company had $150,000 and $200,000 respectively, of accrued liabilities related to health care claims. In order to establish the self-insurance reserves, the Company utilized actuarial estimates of expected claims based on analyses of historical data.
	Fair value of financial instruments
	The Company’s financial instruments consist of cash, accounts receivable and accounts payable. The carrying amounts for cash, accounts receivable and accounts payable approximate their fair value due to the short maturity of these instruments.
	Income taxes
	The Company accounts for income taxes under ASC Topic 740: “Income Taxes.” Under ASC 740, the deferred tax provision is determined using the liability method, whereby deferred tax assets and liabilities are recognized based upon temporary differences between the financial statement and income tax bases of assets and liabilities using presently enacted tax rates. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. In assessing the need for a valuation allowance the Company first considers the reversals of existing temporary deferred tax liabilities and available tax planning strategies.  To the extent these items are not sufficient to cause the realization of deferred tax assets, the Company considers the availability of future taxable income to the extent such income is considered likely to occur based on the Company’s earnings history, current income trends and projections.
	In light of its history of operating losses the Company does not rely on the existence of future taxable income as it currently cannot conclude future taxable income is likely to occur. The Company does rely on reversals of existing temporary deferred tax liabilities and tax planning strategies to the extent available to support the value of its existing deferred tax assets. As of June 30, 2014, the Company’s deferred tax assets exceeded the amount supportable through reversals of existing deferred tax liabilities and tax planning strategies causing for a valuation allowance to be recorded against the excess deferred tax assets.
	The Company recognizes tax liabilities when, despite the Company’s belief that its tax return positions are supportable, the Company believes that certain positions may not be fully sustained upon review by tax authorities. Benefits from tax positions are measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon settlement. To the extent the Company deems it necessary to record a liability for its tax positions, the current portion of the liability is included in income taxes payable and the noncurrent portion is included in other liabilities in balance sheet. If upon the final tax outcome of these matters the ultimate liability is different than the amounts recorded, such differences are reflected in income tax expense in the period in which such determination is made. The Company files a federal and multiple state income tax returns. The Company’s federal and state income tax returns are open for fiscal years ending after June 30, 2011.
	The Company classifies interest expenses on taxes payable as interest expense. Penalties are classified as a component of other expenses.
	Research and development costs
	Research and development costs are expensed as incurred and are included in selling, general and administrative expenses. Research and development expenses for the years ended June 30, 2014, 2013 and 2012 were $657,356, $937,598, and $948,213, respectively.
	Earnings per share
	Basic earnings per share are based on the weighted average number of shares of common stock outstanding during the year. Diluted earnings per share are based on the sum of the weighted average number of shares of common stock and common stock equivalents outstanding during the year. The weighted average number of basic and diluted shares outstanding for the years ended June 30, 2014, 2013 and 2012 was 8,027,147, 8,070,645 and 8,124,386 shares, respectively. The dilutive effect of the Company's employee and director stock option plans are determined by use of the treasury stock method. Potential common shares not included in the calculation of net loss per share, as their effect would be anti-dilutive, are 0, 0 and 3,806 for the years ended June 30, 2014, 2013 and 2012 respectively.
	The following information is necessary to calculate earnings per share for the periods presented:
	Year ended June 30,		2014			2013			2012
	Net loss, as reported		$	-2,805,913		$	-1,256,773		$	-424,426
	Weighted average common shares outstanding			8,027,147			8,070,645			8,124,386
	Effect of dilutive stock options			-			-			-
	Weighted average diluted common shares outstanding			8,027,147			8,070,645			8,124,386
	Net loss per common share
	Basic		$	-0.35		$	-0.16		$	-0.05
	Diluted		$	-0.35		$	-0.16		$	-0.05
	Employee stock options excluded from computation of diluted income per share amounts because their effect would be anti-dilutive			-			-			3,806
	Employee stock-based compensation
	The company follows the provisions of ASC Topic 718: “Compensation – Stock Compensation”, which sets accounting requirements for “share-based” compensation to employees, including employee stock purchase plans, and requires companies to recognize in the statement of operations the grant-date fair value of the stock options and other equity-based compensation.
	The fair value of options granted is estimated on the date of grant using the Black-Scholes option-pricing model. The following table summarizes the weighted average assumptions utilized in the Black-Scholes option pricing model for options granted during the fiscal years ended June 30, 2014, 2013 and 2012.
			2014				2013				2012
	Weighted-average fair value		$	1.04			$	1.15			$	1.6
	Weighted-average volatility			45	%			46	%			46	%
	Weighted-average expected life (in years)			6				6				6
	Weighted-average risk-free interest rate			1.68	%			0.93	%			1.67	%
	Dividend yield			0	%			0	%			0	%
	Expected volatility is based on the historical volatility of the Company’s common stock to estimate future volatility. The risk-free rates are taken from rates as published by the Federal Reserve and represent the yields on actively traded treasury securities for terms equal or approximately equal to the expected terms of the options. The expected term is calculated using the SEC Staff Accounting Bulletin 107 (ASC 718-10-S99) simplified method. The dividend yield is zero based on the fact that the Company has no intention of paying dividends in the near term.
	Share-based compensation expense included in the Statement of Operations for the fiscal years ended June 30, 2014, 2013 and 2012 was approximately $10,000, $44,000 and $44,000, respectively. Unrecognized shared-based compensation cost related to unvested stock options as of June 30, 2014 amounts to approximately $2,000. The cost is expected to be recognized over the next fiscal year.
	The Company recognized income tax benefits for share-based compensation arrangements of approximately $4,000, $18,000 and $18,000 for the years ended June 30, 2014, 2013 and 2012, respectively.
	No stock options were exercised during fiscal years 2014, 2013 and 2012.
Recently Issued Accounting Pronouncements
In May 2014, the Financial Accounting Standards Board (FASB) issued ASU No. 2014-09, “Revenue from Contracts with Customers” (ASU 2014-09), which supersedes nearly all existing revenue recognition guidance under accounting principles generally accepted in the Unites States of America (“U.S. GAAP”). The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing U.S. GAAP.
The standard is effective for annual periods beginning after December 15, 2016, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). The Company is currently evaluating which transition approach to use and the full impact this ASU will have on our future financial statements.

Financing

Financing	12 Months Ended
	Jun. 30, 2014
Debt Disclosure [Abstract]	'
Debt Disclosure [Text Block]	'
		3	Financing
	The Company is party to a Loan and Security Agreement, dated November 17, 2009, with Enterprise Bank & Trust (the “Credit Agreement”) pursuant to which the Company obtained a secured revolving credit facility. Currently the agreement provides for borrowing availability of up to $5,000,000 (the “Credit Facility”). At June 30, 2014, the Company had $5,000,000 available for borrowing on the line of credit. The Company’s obligations under the Credit Facility are secured by certain assets of the Company pursuant to the terms and subject to the conditions set forth in the Credit Agreement.
	The Credit Facility was amended on November 12, 2013 extending the maturity date to November 11, 2014. The Credit Facility will be available on a revolving basis until it expires on November 11, 2014, at which time all amounts outstanding under the Credit Facility will be due and payable. Advances under the Credit Facility will be made pursuant to a Revolving Credit Note executed by the Company in favor of Enterprise Bank & Trust. Such advances will bear interest at a rate equal to 3.50% in excess of the 30-day LIBOR rate. Advances may be prepaid in whole or in part without premium or penalty.
	Under the Credit Agreement, advances are generally subject to customary borrowing conditions. The Credit Agreement also contains covenants with which the Company must comply during the term of the Credit Facility. Among other things, such covenants restrict the Company’s ability to incur certain additional debt; make specified restricted payments, dividends and capital expenditures; authorize or issue capital stock; enter into certain transactions with affiliates; consolidate or merge with or acquire another business; sell certain of its assets or dissolve or wind up the Company. The Credit Agreement also contains certain events of default that are customary for financings of this type including, without limitation: the failure to pay principal, interest, fees or other amounts when due; the breach of specified representations or warranties contained in the loan documents; cross-default with certain other indebtedness of the Company; the entry of uninsured judgments that are not bonded or stayed; failure to comply with the observance or performance of specified agreements contained in the loan documents; commencement of bankruptcy or other insolvency proceedings; and the failure of any of the loan documents entered into in connection with the Credit Facility to be in full force and effect. After an event of default, and upon the continuation thereof, the principal amount of all loans made under the Credit Facility would bear interest at a rate per annum equal to 4.00% above the otherwise applicable interest rate (provided, that the interest rate may not exceed the highest rate permissible under law), and the lender would have the option to accelerate maturity and payment of the Company’s obligations under the Credit Facility.
	The 30-day LIBOR rate was 0.15% on June 30, 2014.
	At June 30, 2014 the Company had no aggregate indebtedness, including capital lease obligations, short-term debt and long term debt.
	The Company was in compliance with all of the covenants associated with the Credit Facility at June 30, 2014.

Lease_Commitments

Lease Commitments	12 Months Ended
	Jun. 30, 2014
Leases [Abstract]	'
Leases of Lessor Disclosure [Text Block]	'
		4	Lease Commitments
	The Company leases certain of its equipment under non-cancelable operating lease agreements. Minimum lease payments under operating leases at June 30, 2014 are as follows:
	Fiscal Year		Operating
			Leases
	2015			82,021
	2016			60,575
	2017			53,246
	2018			50,630
	2019			3,934
	Total minimum lease payments		$	250,406
	Rental expense incurred on operating leases in fiscal 2014, 2013, and 2012 totaled $236,826, $255,517 and $238,486, respectively.

Income_Taxes

Income Taxes	12 Months Ended
	Jun. 30, 2014
Income Tax Disclosure [Abstract]	'
Income Tax Disclosure [Text Block]	'
	5	Income Taxes
	The provision for (benefit from) income taxes consists of the following:
			2014		2013		2012
	Current:
	Federal		$	-	$	-	$	-
	State			12,933		17,661		11,581
	Total current			12,933		17,661		11,581
	Deferred:
	Federal			-1,050,750		-698,712		-252,778
	State			-102,199		-58,987		-4,723
	Valuation Allowance			800,203		-		-
	Total deferred			-352,746		-757,699		-257,501
			$	-339,813	$	-740,038	$	-245,920
	A reconciliation of income taxes, with the amounts computed at the statutory federal rate is as follows:
			2014		2013		2012
	Computed tax at federal statutory rate		$	-1,069,547	$	-678,916	$	-227,917
	State income taxes, net of federal tax (benefit) provision			-62,712		-32,502		-4,982
	Non deductible expenses			18,141		20,162		17,572
	Federal research credit			-15,328		-43,095		-31,507
	Other, net			-10,570		-5,687		914
	Valuation Allowance			800,203		-		-
	Total		$	-339,813	$	-740,038	$	-245,920
	The deferred tax assets and deferred tax liabilities recorded on the balance sheet as of June 30, 2014 and 2013 are as follows:
			2014				2013
			Deferred Tax		Deferred Tax		Deferred Tax		Deferred Tax
			Assets		Liabilities		Assets		Liabilities
	Current:
	Bad debts		$	40,000	$	—	$	40,000	$	—
	Prepaid expenses			—		22,971		—		16,646
	Accrued liabilities			304,747		—		335,744		—
	Inventory			—		1,152,722		—		1,204,637
				344,747		1,175,693		375,744		1,221,283
	Non Current:
	Depreciation			—		535,510		—		479,840
	Net operating loss and credit carryforwards			2,987,082		—		1,771,164		—
	Intangible assets			1,306		—		143		—
	Accrued pension liability			29,700		—		32,840		—
	Stock options			363,385		—		368,941		—
	Other			—		49,327		—		25,549
				3,381,473		584,837		2,173,088		505,389
	Valuation Allowance			-800,203		—		—		—
	Total deferred taxes		$	2,926,017	$	1,760,530	$	2,548,832	$	1,726,672
	At June 30, 2014 there were $7.6 million dollars of federal net operating loss carryforwards which will expire in 2031 through 2034. In addition, the Company has state tax net operating losses of approximately $6.6 million that expire in varying years from 2029 through 2034.
	The Company files a federal and multiple state income tax returns. The Company’s federal and state income tax returns are open for fiscal years ending after June 30, 2011.
	Management of the Company is not aware of any additional needed liability for unrecognized tax benefits at June 30, 2014 and 2013.

Employee_Retirement_Benefits

Employee Retirement Benefits

12 Months Ended

Jun. 30, 2014

Compensation and Retirement Disclosure [Abstract]

'

Pension and Other Postretirement Benefits Disclosure [Text Block]

'

6

Employee Retirement Benefits

The Company offers a retirement savings plan under Section 401(k) of the Internal Revenue Code to certain eligible salaried employees. Each employee may elect to enter a written salary deferral agreement under which a portion of such employee's pre-tax earnings may be contributed to the plan.

During the fiscal years ended June 30, 2014, 2013 and 2012, the Company made contributions of $277,374, $278,212, and $247,576, respectively, to the retirement savings plan. The Company contributes 2% of eligible salaried employee’s annual income to the plan. In addition, the Company provides a 25% match on the first 8% of employee deferrals for eligible employees.

The risk of participating in multi-employer pension plan is different from single-employer plans. Assets contributed to a multi-employer plan by one employer may be used to provide benefits to employees of other participating employers. If a participating employer stops contributing to the plan, the unfunded obligations of the plan may be borne by the remaining participating employers.

The Company’s participation in a multi-employer pension plan for the year ended June 30, 2014, is outlined in the table below. The “EIN/PN” column provides the Employee Identification Number (EIN) and the three-digit plan number (PN). The most recent Pension Protection Act (PPA) zone status for 2013 and 2012 is for the plan year-ends as indicated below. The zone status is based on information that the Company obtained from the Notes to the Financial Statements included with the plan’s Form 5500. Among other factors, plans in the red zone are between 65 percent and 80 percent funded, and plans in the green zone are at least 80 percent funded. The “FIP/RP Status Pending/Implemented” column indicates plans for which a financial improvement plan (FIP) or a rehabilitation plan (RP) is either pending or has been implemented. In addition to regular plan contributions, the Company may be subject to a surcharge if the plan is in the red zone. The “Surcharge Imposed” column indicates whether a surcharge has been imposed on contributions to the plan. The last column lists the expiration date(s) of the collective-bargaining agreement (CBA) to which the plan is subject.

PPA Zone Status

Contributions by the Company

FIP/RP

Status

Pending/

Surcharge

Expiration

Pension Trust Fund

EIN/PN

2013

2012

Implemented

2014

2013

2012

Imposed

Date of CBA

District No. 9 International

51-0138317/001

Green

Green

Association of

12/31/12

12/31/11

Implemented

$

293,377

$

309,373

$

331,154

No

5/31/15

Machinist and

Aerospace Workers

Pension Plan

The Company was not listed in the Form 5500 for the above plan as of the plan year ends as providing more than 5 percent of total contributions.

Stock_Based_Compensation

Stock Based Compensation	12 Months Ended
	Jun. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	'
		7	Stock Based Compensation
	The Company has established a 1994 Employee Stock Option Plan, 1999 Incentive Stock Plan, and a 2009 Incentive Stock Plan (collectively the “Employee Plans”). The Employee Plans provide for the granting of options to the Company's executive officers and key employees to purchase shares of common stock at prices equal to the fair market value of the stock on the date of grant. Options to purchase up to 2,150,000 shares of common stock may be granted under the Employee Plans. Options generally become exercisable ratably over a four year period or one-fourth of the shares covered thereby on each anniversary of the date of grant, commencing on the first or second anniversary of the date granted. The right to exercise the options generally expires in ten years from the date of grant, or earlier if an option holder ceases to be employed by the Company.
	In addition, the Company has established a 1995 Directors Non-Qualified Stock Option Plan, 2005 Directors Non-Qualified Stock Option Plan, and a 2013 Incentive Plan for Non-Employee Directors (collectively the “Directors Plans”). The Directors Plans provide for the granting of options to the Company's directors who are not employees of the Company to purchase shares of common stock at prices equal to the fair market value of the stock on the date of grant. Options to purchase up to 300,000 shares of common stock may be granted under the Directors Plans. Options shall become exercisable with respect to one-fourth of the shares covered thereby on each anniversary of the date of grant, commencing on the second anniversary of the date granted, except for certain options which become exercisable with respect to all of the shares covered thereby one year after the grant date. The right to exercise the options expires in ten years from the date of grant, or earlier if an option holder ceases to be a director of the Company.
	Upon stock-settled compensation exercises and awards, the Company issues new shares of common stock.
	A summary of stock option transactions in fiscal 2012, 2013 and 2014, respectively, pursuant to the Employee Plans and the Directors Plans is as follows:
								Weighted
								Average
					Weighted			Remaining		Aggregate
					Average			Contractual		Intrinsic
			Shares		Exercise Price			Term (years)		Value
	30-Jun-11			448,000	$	4.38
	Options Granted			51,000	$	3.51
	Options Exercised			0	$	0
	Options Forfeited or Expired			-31,000	$	3.4
	30-Jun-12			468,000	$	4.35			4.1	$	330
	30-Jun-12			468,000	$	4.35
	Options Granted			6,000	$	2.59
	Options Exercised			0	$	0
	Options Forfeited or Expired			-1,500	$	2.9
	30-Jun-13			472,500	$	4.34			3.2	$	960
	30-Jun-13			472,500	$	4.34
	Options Granted			6,000	$	2.31
	Options Exercised			0	$	0
	Options Forfeited or Expired			-12,500	$	4.74
	30-Jun-14			466,000	$	4.3			2.3	$	660
	Exercisable at June 30, 2014			460,000	$	4.32			2.2	$	-
	The following table provides additional information for options outstanding and exercisable at June 30, 2014:
	Options Outstanding
	Range of Exercise Prices			Number	Weighted Average		Weighted Average
					Remaining Life		Exercise Price
	2.31 - 4.24			69,000	7.2 years		$	3.37
	4.25 - 4.25			320,000	1.2 years		$	4.25
	4.26 - 6.84			77,000	2.7 years		$	5.33
	$2.31 - 6.84			466,000	2.3 years		$	4.3
	Options Exercisable
	Range of Exercise Prices			Number	Weighted Average
					Exercise Price
	2.31 - 4.24			63,000	$	3.47
	4.25 - 4.25			320,000	$	4.25
	4.26 - 6.84			77,000	$	5.33
	$2.31 - 6.84			460,000	$	4.32
	See Note 2 for discussion of accounting for stock awards and related fair value disclosures.

Supplemental_Balance_Sheet_Inf

Supplemental Balance Sheet Information	12 Months Ended
	Jun. 30, 2014
Supplemental Balance Sheet Information [Abstract]	'
Supplemental Balance Sheet Disclosures [Text Block]	'
		8	Supplemental Balance Sheet Information
			June 30,
			2014			2013
	Inventories
	Work in progress		$	616,474		$	663,100
	Component parts			7,605,543			7,530,506
	Finished goods			2,617,799			2,457,337
	Reserve for obsolete and excess inventory			-1,433,718			-1,312,600
			$	9,406,098		$	9,338,343
			Estimated
			Useful Life
			(years)
	Property, plant and equipment
	Machinery and equipment		10-Mar		$	14,609,438		$	14,306,930
	Buildings		28-35			13,048,090			12,912,094
	Land and land improvements		7-May			934,216			934,216
	Total property, plant and equipment at cost					28,591,744			28,153,240
	Less accumulated depreciation and amortization					-19,656,143			-18,430,896
					$	8,935,601		$	9,722,344
	Depreciation expense was  approximately $1.2 million, $1.2 million, and $1.3 million for the fiscal years ended June 30, 2014, 2013 and 2012, respectively.
	Other accrued liabilities
	Accrued compensation expense		$	1,064,354		$	1,187,224
	Customer deposits			252,496			359,597
	Other			307,336			314,420
			$	1,624,186		$	1,861,241

Demutualization_of_Product_Lia

Demutualization of Product Liability Insurer	12 Months Ended
	Jun. 30, 2014
Demutualization Of Product Liability Insurer [Abstract]	'
Demutualization Of Product Liability Insurer [Text Block]	'
		9	Demutualization of Product Liability Insurer
	The Company’s product liability insurer, Medmarc Insurance Group, demutualized and was acquired by ProAssurance Corporation on January 1, 2013. As a policyholder of a mutual insurance company, Allied was entitled to receive a portion of the proceeds received by Medmarc. In January 2013 the Company received a cash payment of approximately $516,000 as its share of these proceeds. These proceeds are included in Other Income and Expenses. The Company does not anticipate receiving future proceeds of a material amount.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Jun. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies Disclosure [Text Block]	'
		10	Commitments and Contingencies
	Legal Claims
	The Company is subject to various investigations, claims and legal proceedings covering a wide range of matters that arise in the ordinary course of its business activities. The Company intends to continue to conduct business in such a manner as to avert any FDA action seeking to interrupt or suspend manufacturing or require any recall or modification of products.
	The Company has recognized the costs and associated liabilities only for those investigations, claims and legal proceedings for which, in its view, it is probable that liabilities have been incurred and the related amounts are estimable. Based upon information currently available, management believes that existing accrued liabilities are sufficient and that it is not reasonably possible at this time that any additional liabilities will result from the resolution of these matters that would have a material adverse effect on the Company’s results of operations, financial position, or cash flows.
	Stuyvesant Falls Power Litigation. The Company is currently involved in litigation with Niagara Mohawk Power Corporation d/b/a National Grid (“Niagara”) and other parties, which provides electrical power to the Company’s facility in Stuyvesant Falls, New York. In fiscal year 2011, Niagara began sending invoices to the Company for electricity used at the Company’s Stuyvesant Falls plant. The Company maintains in its defense of the lawsuit that it is entitled to a certain amount of free electricity based on covenants running with the land which have been honored for more than a century. Niagara’s attempts to collect such invoices were stopped in December 2010 by a temporary restraining order, although a court has not yet ruled on the merits of all of Niagara’s claims. Among other things, Niagara seeks as damages the value of electricity received by the Company without charge. While the total value of electricity at issue in the litigation is not known with certainty, Niagara alleges in its Motion For Summary Judgment, filed on March 14, 2014, damages of approximately $492,000 in free electricity since May 2010. Alternatively, Niagara asserts that, in the event that the free power covenant is still enforceable, the Company is still responsible for delivery fees relating to any free power to which it is entitled. The Company filed its own Motion For Summary Judgment on March 14, 2014, seeking dismissal of Niagara’s claims and oral arguments on the motions were held on June 13, 2014. As of June 30, 2014, the Company has not recorded a provision for this matter as management intends to vigorously defend this litigation and believes it is not probable that the Company will be required to pay for electricity as Niagara claims. The Company believes, however, that any liability it may incur should it not prevail in the litigation would not have a material adverse effect on its financial condition, its result of operations, or its cash flows.
	Dräger Patent Litigation. On or about October 4, 2013, Dräger Medical GmbH and certain affiliates (the “Dräger Plaintiffs”) filed a patent infringement lawsuit against the Company in the District of Delaware, asserting that the Company infringes United States Patent Nos. 7,487,776 and 8,286,633, both protecting particular combinations of carbon dioxide absorption cartridges and adapters which fit on anesthesia machines. The Dräger Plaintiffs assert that the Company’s sales of certain models of its Litholyme and Carbolyme single-use carbon dioxide absorption cartridges infringe both patents. The Company has answered the Complaint, asserting invalidity of the patents, non-infringement, and implied license under the doctrine of permissive repair.
	On October 25, 2013, the Dräger Plaintiffs filed a motion for preliminary injunction requesting that the Company be enjoined from selling certain models of its Litholyme and Carbolyme cartridges during the pendency of the litigation. A hearing on the motion for preliminary injunction was held on February 7, 2014. On March 24, 2014, the Court ruled in Allied’s favor and denied Dräger’s motion for a preliminary injunction, stating among other things that Dräger had not carried its burden of showing that Allied had infringed Dräger’s patents.
	As of June 30, 2014, the Company has not recorded a provision for this matter because the Company cannot estimate a possible loss or range of loss for this matter because the Dräger Plaintiffs have not specified damages claimed and the proceedings are in the early stages. The Company intends to defend against any further litigation brought by the Dräger Plaintiffs and pursue counterclaims for invalidity, non-infringement, and implied license.
	Employment Contract
	In March 2007, the Company entered into a three year employment contract with its chief executive officer. The contract is subject to automatic annual renewals after the initial term unless notification is given. The contract was  amended and restated in December 2009 without extending its term. The contract includes termination without cause and change of control provisions, under which the chief executive officer is entitled to receive specified severance payments generally equal to two times ending annual salary if the Company terminates his employment without cause or he voluntarily terminates his employment with “good reason.” “Good Reason” generally includes changes in the scope of his duties or location of employment but also includes (i) the Company’s written election not to renew the Employment Agreement and (ii) certain voluntary resignations by the chief executive officer following a “Change of Control” as defined in the Agreement.

Segment_Information

Segment Information	12 Months Ended
	Jun. 30, 2014
Segment Reporting [Abstract]	'
Segment Reporting Disclosure [Text Block]	'
		11	Segment Information
	The Company operates in one segment consisting of the manufacturing, marketing and distribution of a variety of respiratory products used in the health care industry to hospitals, hospital equipment dealers, hospital construction contractors, home health care dealers and emergency medical product dealers. The Company’s product lines include respiratory care products, medical gas equipment and emergency medical products. The Company does not have any one single customer that represents more than 10 percent of total sales. Sales by region, and by product, are as follows:
	Sales by Region
			2014		2013		2012
	Domestic United States		$	27,214,060	$	29,180,042	$	33,816,317
	Europe			858,735		1,421,347		1,510,197
	Canada			758,392		673,011		603,530
	Latin America			4,291,530		4,113,201		4,883,288
	Middle East			1,214,389		1,228,318		925,658
	Far East			2,011,714		1,841,771		1,594,172
	Other International			21,796		94,084		112,459
			$	36,370,616	$	38,551,774	$	43,445,621
	Sales by Product
			2014		2013		2012
	Respiratory care products		$	9,688,486	$	8,944,319	$	10,082,450
	Medical gas equipment			19,425,522		21,870,840		24,803,614
	Emergency medical products			7,256,608		7,736,615		8,559,557
			$	36,370,616	$	38,551,774	$	43,445,621

Quarterly_Financial_Data_unaud

Quarterly Financial Data (unaudited)	12 Months Ended
	Jun. 30, 2014
Quarterly Financial Information Disclosure [Abstract]	'
Quarterly Financial Information [Text Block]	'
	12.    Quarterly Financial Data (unaudited)
	Summarized quarterly financial data for fiscal 2014 and 2013 appears below (all amounts in thousands except per share amounts):
		June 30,		March 31,		Dec. 31,		Sept. 30,		June 30,		March 31,		Dec. 31,		Sept. 30,
	Three months ended,	2014		2014		2013		2013		2013		2013		2012		2012
	Net sales	$	9,798	$	9,116	$	8,749	$	8,708	$	10,133	$	9,210	$	9,921	$	9,287
	Gross profit		1,861		1,748		1,944		1,761		2,478		1,680		2,106		1,979
	Loss from operations		-395		-960		-892		-862		-122		-960		-751		-660
	Net loss		-347		-969		-899		-591		-98		-279		-469		-411
	Basic loss per share		-0.04		-0.12		-0.11		-0.07		-0.01		-0.03		-0.06		-0.05
	Diluted loss per share		-0.04		-0.12		-0.11		-0.07		-0.01		-0.03		-0.06		-0.05
	Earnings per share is computed independently for each of the quarters presented. Therefore, the sum of the quarterly amounts will not necessarily equal the total for the year.

Baralyme_Agreement

Baralyme Agreement	12 Months Ended
	Jun. 30, 2014
Deferred Revenue Disclosure [Abstract]	'
Deferred Revenue Disclosure [Text Block]	'
	13.   Baralyme® Agreement
	On August 27, 2004, Allied entered into an agreement with Abbott Laboratories (“Abbott”) pursuant to which Allied agreed to cease production of its product Baralyme®, and to effect the withdrawal of Baralyme® product held by distributors. The agreement permits Allied to pursue the development of a new carbon dioxide absorbent product. Baralyme®, a carbon dioxide absorbent product, has been used safely and effectively in connection with inhalation anesthetics since its introduction in the 1920s. In recent years, the number of inhalation anesthetics has increased, giving rise to concerns regarding the use of Baralyme® in conjunction with these newer inhalation anesthetics if Baralyme® has been allowed, contrary to recommended practice, to become desiccated. The agreement also provides that, for a period of eight years, Allied will not manufacture, distribute, promote, market, sell, commercialize or donate any Baralyme® product or similar product based upon potassium hydroxide and will not develop or license any new carbon dioxide absorbent product containing potassium hydroxide.
	In consideration of the foregoing, Abbott agreed to pay Allied an aggregate of $5,250,000 of which $1,530,000 was paid on September 30, 2004 and the remainder payable in four equal annual installments of $930,000 due on July 1, 2005 through July 1, 2008.
	The initial payment of $1,530,000 from Abbott was received on September 30, 2004. The agreement required Abbott to pay Allied $600,000 for reimbursement of Allied’s cost incurred in connection with withdrawal of Baralyme® from the market, the disposal of such product, and severance payments payable as a result of such withdrawal. The payments by Abbott have been included in net sales, in accordance with ASC Topic 605: “Revenue Recognition.” The Company is the primary obligor in the arrangement. It has sole authority to determine the method of withdrawal of Baralyme® and discretion in such matters as employee layoffs, disposal methods, and customer communications regarding the sale of replacement products. The costs of executing the withdrawal are the sole responsibility of the Company.
	The payments received from Abbott have been recognized into income, as net sales, over the eight-year term of the agreement. Allied has no further obligations under this agreement which would require the Company to repay these amounts or otherwise impact this accounting treatment. During the fiscal years ended June 30, 2014, 2013, and 2012, Allied recognized $0, $114,700 and $688,200, respectively into income as net sales in each year. The agreement expired in August 2012 and no further income will be recognized from the agreement after such expiration.
	A reconciliation of deferred revenue resulting from the agreement with Abbott, with the amounts received under the agreement, and amounts recognized as net sales is as follows:
		Twelve Months ended
		June 30,
		2014		2013
	Beginning balance	$	-	$	114,700
	Revenue recognized as net sales		-		-114,700
			-		0
	Less - Current portion of deferred revenue		-		0
		$	-	$	0

Share_Repurchases

Share Repurchases	12 Months Ended
	Jun. 30, 2014
Share Repurchases [Abstract]	'
Share Repurchases [Text Block]	'
	14.  Share Repurchases
	On November 21, 2012 the Company’s Board of Directors approved the purchase of up to 100,000 shares of the Company’s common stock. This authority terminated on February 19th, 2013. Pursuant to this authorization, the Company repurchased 94,139 shares of stock at an average price of $2.54 for an aggregate total purchase price of $240,952.
	On February 25, 2013 the Company’s Board of Directors authorized the repurchase of up to 100,000 shares of the Company’s common stock for a period of 90 days. Repurchases may be made in the open market or in privately negotiated transactions, with the timing and terms of such transaction in the discretion of the Chairman of the Board unless terminated by the Board, the repurchase authority renews for successive 90 day periods. The repurchase authority may be terminated by the Board at any time and without notice. Pursuant to this authorization, the Company repurchased a total of 3,100 shares on February 26, 2013 at an average price of $2.69 per share for an aggregate total purchase price of $8,408.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Jun. 30, 2014

Accounting Policies [Abstract]

'

Use of Estimates, Policy [Policy Text Block]

'

Use of estimates

The policies utilized by the Company in the preparation of the financial statements conform to accounting principles generally accepted in the United States of America, and require management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual amounts could differ from those estimates.

Revenue Recognition, Policy [Policy Text Block]

'

Revenue recognition

Revenue is recognized for all sales, including sales to agents and distributors, at the time products are shipped and title has transferred, provided that a purchase order has been received or a contract executed, there are not uncertainties regarding customer acceptance, the sales price is fixed and determinable and collectability is reasonably assured. Sales discounts, returns and allowances are included in net sales, and the provision for doubtful accounts is included in selling, general and administrative expenses. Additionally, it is the Company’s practice to include revenues generated from freight billed to customers in net sales with corresponding freight expense included in cost of sales in the Statement of Operations. The Company reports sales taxes on sales transactions on a net basis in the Statement of Operations, and therefore does not include sales taxes in revenues or costs.

The sales price is fixed by Allied’s acceptance of the buyer’s firm purchase order. The sales price is not contingent, or subject to additional discounts. Allied’s standard shipment terms are “F.O.B. shipping point” as stated in Allied’s Terms and Conditions of Sale. The customer is responsible for obtaining insurance for and bears the risk of loss for product in-transit. Additionally, sales to customers do not include the right to return merchandise without the prior consent of Allied. In those cases where returns are accepted, product must be current and restocking fees must be paid by the respective customer. A provision has been made for estimated sales returns and allowances. These estimates are based on historical analysis of credit memo data and returns.

Allied does not provide installation services for its products. Most products shipped are ready for immediate use by the customer. The Company’s in-wall medical system components, central station pumps and compressors, and headwalls do require installation by the customer. These products are typically purchased by a third-party contractor who is ultimately responsible for installation services. Accordingly, the customer purchase order or contract does not require customer acceptance of the installation prior to completion of the sale transaction and revenue recognition. Allied’s standard payment terms are net 30 days from the date of shipment, and payment is specifically not subject to customer inspection or acceptance, as stated in Allied’s Terms and Conditions of Sale. The buyer becomes obligated to pay Allied at the time of shipment. Allied requires credit applications from its customers and performs credit reviews to determine the creditworthiness of new customers. Allied requires letters of credit, where warranted, for international transactions. Allied also protects its legal rights under mechanics lien laws when selling to contractors.

Allied does offer limited warranties on its products.  The standard warranty period is one year.  The Company’s cost of providing warranty service for its products for the years ended June 30, 2014, 2013, and 2012 was $113,209, $150,944, and $152,625, respectively.  The related liability for warranty service amounted to $130,000 at June 30, 2014 and 2013.

Advertising Costs, Policy [Policy Text Block]

'

Marketing and Advertising Costs

Promotional and advertising costs are expensed as incurred and are included in selling, general and administrative expenses in the Statement of Operations. Advertising expenses for the years ended June 30, 2014, 2013 and 2012 were $17,904, $46,691, and $46,278, respectively.

Cash and Cash Equivalents, Policy [Policy Text Block]

'

Cash and cash equivalents

For purposes of the statement of cash flows, the Company considers all highly liquid investments with a maturity of three months or less when acquired to be cash equivalents.

The Company maintains funds in bank accounts that, at times, may exceed the limit insured by the Federal Deposit Insurance Corporation. The risk of loss attributable to these uninsured balances is mitigated by depositing funds only in high credit quality financial institutions. The Company has not experienced any losses in such accounts.

Foreign Currency Transactions and Translations Policy [Policy Text Block]

'

Foreign currency transactions

Allied has international sales which are denominated in U.S. dollars, the functional currency for these transactions.

Accounts Receivable And Concentrations Of Credit Risk [Policy Text Block]

'

Accounts receivable and concentrations of credit risk

Accounts receivable are recorded at the invoiced amount. The Company performs ongoing credit evaluations of its customers and generally does not require collateral. The Company maintains reserves for potential credit losses based on past experience and an analysis of current amounts due, and historically such losses have been within management's expectations. The Company maintains an allowance for doubtful accounts to reflect the uncollectibility of accounts receivable based on past collection history and specific risks indentified among uncollected accounts. Accounts receivable are charged to the allowance for doubtful accounts when the Company determines that the receivable will not be collected and/or when the account has been referred to a third party collection agency. The Company’s customers can be grouped into three main categories: medical equipment distributors, construction contractors and health care institutions. At June 30, 2014, the Company believes that it has no significant concentration of credit risk.

Inventory, Policy [Policy Text Block]

'

Inventories

Inventories are stated at the lower of cost, determined using the last-in, first-out (“LIFO”) method, or market. If the first-in, first-out method (which approximates replacement cost) had been used in determining cost, inventories would have been $2,473,787 and $2,343,788 higher at June 30, 2014 and 2013, respectively. Changes in the LIFO reserve are included in cost of sales. Cost of sales was reduced by $0, $171,918, and $164,645 in fiscal 2014, 2013, and 2012 respectively, as a result of LIFO liquidations. Costs in inventory include raw materials, direct labor and manufacturing overhead.

Inventory is recorded net of a reserve for obsolete and excess inventory which is determined based on an analysis of inventory items with no usage in the preceding year and for inventory items for which there is greater than two years’ usage on hand. The reserve for obsolete and excess inventory was $1,433,718 and $1,312,600 at June 30, 2014 and 2013, respectively.

Property, Plant and Equipment, Policy [Policy Text Block]

'

Property, plant and equipment

Property, plant and equipment are recorded at cost and are depreciated using the straight-line method over the estimated useful lives of the assets, which range from 3 to 35 years. Expenditures for repairs, maintenance and renewals are charged to income as incurred. Expenditures, which improve an asset or extend its estimated useful life, are capitalized. When properties are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the accounts and any gain or loss is included in income.

Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]

'

Impairment of long-lived assets

The Company evaluates impairment of long-lived assets under the provisions of ASC Topic 360: “Property, Plant and Equipment.” ASC 360 provides a single accounting model for long-lived assets to be disposed of and reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. Under ASC 360, if the sum of the expected future cash flows (undiscounted and without interest charges) of the long-lived assets is less than the carrying amount of such assets, an impairment loss will be recognized. No impairment losses of long-lived assets or identifiable intangibles were recorded by the Company for fiscal years ended June 30, 2014, 2013, and 2012.

Collective Bargaining Agreement [Policy Text Block]

'

Collective Bargaining Agreement

At June 30, 2014, the Company had approximately 243 full-time employees. Approximately 148 employees in the Company’s principal manufacturing facility located in St. Louis, Missouri, are covered by a collective bargaining agreement that will expire on May 31, 2015.

Self Insurance [Policy Text Block]

'

Self-insurance

The Company maintains a self-insurance program for a portion of its health care costs. Self-insurance costs are accrued based upon the aggregate of the liability for reported claims and the estimated liability for claims incurred but not reported. As of June 30, 2014 and 2013, the Company had $150,000 and $200,000 respectively, of accrued liabilities related to health care claims. In order to establish the self-insurance reserves, the Company utilized actuarial estimates of expected claims based on analyses of historical data.

Fair Value of Financial Instruments, Policy [Policy Text Block]

'

Fair value of financial instruments

The Company’s financial instruments consist of cash, accounts receivable and accounts payable. The carrying amounts for cash, accounts receivable and accounts payable approximate their fair value due to the short maturity of these instruments.

Income Tax, Policy [Policy Text Block]

'

Income taxes

The Company accounts for income taxes under ASC Topic 740: “Income Taxes.” Under ASC 740, the deferred tax provision is determined using the liability method, whereby deferred tax assets and liabilities are recognized based upon temporary differences between the financial statement and income tax bases of assets and liabilities using presently enacted tax rates. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. In assessing the need for a valuation allowance the Company first considers the reversals of existing temporary deferred tax liabilities and available tax planning strategies.  To the extent these items are not sufficient to cause the realization of deferred tax assets, the Company considers the availability of future taxable income to the extent such income is considered likely to occur based on the Company’s earnings history, current income trends and projections.

In light of its history of operating losses the Company does not rely on the existence of future taxable income as it currently cannot conclude future taxable income is likely to occur. The Company does rely on reversals of existing temporary deferred tax liabilities and tax planning strategies to the extent available to support the value of its existing deferred tax assets. As of June 30, 2014, the Company’s deferred tax assets exceeded the amount supportable through reversals of existing deferred tax liabilities and tax planning strategies causing for a valuation allowance to be recorded against the excess deferred tax assets.

The Company recognizes tax liabilities when, despite the Company’s belief that its tax return positions are supportable, the Company believes that certain positions may not be fully sustained upon review by tax authorities. Benefits from tax positions are measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon settlement. To the extent the Company deems it necessary to record a liability for its tax positions, the current portion of the liability is included in income taxes payable and the noncurrent portion is included in other liabilities in balance sheet. If upon the final tax outcome of these matters the ultimate liability is different than the amounts recorded, such differences are reflected in income tax expense in the period in which such determination is made. The Company files a federal and multiple state income tax returns. The Company’s federal and state income tax returns are open for fiscal years ending after June 30, 2011.

The Company classifies interest expenses on taxes payable as interest expense. Penalties are classified as a component of other expenses.

Research and Development Expense, Policy [Policy Text Block]

'

Research and development costs

Research and development costs are expensed as incurred and are included in selling, general and administrative expenses. Research and development expenses for the years ended June 30, 2014, 2013 and 2012 were $657,356, $937,598, and $948,213, respectively.

Earnings Per Share, Policy [Policy Text Block]

'

Earnings per share

Basic earnings per share are based on the weighted average number of shares of common stock outstanding during the year. Diluted earnings per share are based on the sum of the weighted average number of shares of common stock and common stock equivalents outstanding during the year. The weighted average number of basic and diluted shares outstanding for the years ended June 30, 2014, 2013 and 2012 was 8,027,147, 8,070,645 and 8,124,386 shares, respectively. The dilutive effect of the Company's employee and director stock option plans are determined by use of the treasury stock method. Potential common shares not included in the calculation of net loss per share, as their effect would be anti-dilutive, are 0, 0 and 3,806 for the years ended June 30, 2014, 2013 and 2012 respectively.

The following information is necessary to calculate earnings per share for the periods presented:

Year ended June 30,

2014

2013

2012

Net loss, as reported

$

-2,805,913

$

-1,256,773

$

-424,426

Weighted average common shares outstanding

8,027,147

8,070,645

8,124,386

Effect of dilutive stock options

-

-

-

Weighted average diluted common shares outstanding

8,027,147

8,070,645

8,124,386

Net loss per common share

Basic

$

-0.35

$

-0.16

$

-0.05

Diluted

$

-0.35

$

-0.16

$

-0.05

Employee stock options excluded from computation of diluted income per share amounts because their effect would be anti-dilutive

-

-

3,806

Compensation Related Costs, Policy [Policy Text Block]

'

Employee stock-based compensation

The company follows the provisions of ASC Topic 718: “Compensation – Stock Compensation”, which sets accounting requirements for “share-based” compensation to employees, including employee stock purchase plans, and requires companies to recognize in the statement of operations the grant-date fair value of the stock options and other equity-based compensation.

The fair value of options granted is estimated on the date of grant using the Black-Scholes option-pricing model. The following table summarizes the weighted average assumptions utilized in the Black-Scholes option pricing model for options granted during the fiscal years ended June 30, 2014, 2013 and 2012.

2014

2013

2012

Weighted-average fair value

$

1.04

$

1.15

$

1.6

Weighted-average volatility

45

%

46

%

46

%

Weighted-average expected life (in years)

6

6

6

Weighted-average risk-free interest rate

1.68

%

0.93

%

1.67

%

Dividend yield

0

%

0

%

0

%

New Accounting Pronouncements, Policy [Policy Text Block]

'

Recently Issued Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (FASB) issued ASU No. 2014-09, “Revenue from Contracts with Customers” (ASU 2014-09), which supersedes nearly all existing revenue recognition guidance under accounting principles generally accepted in the Unites States of America (“U.S. GAAP”). The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing U.S. GAAP.

The standard is effective for annual periods beginning after December 15, 2016, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). The Company is currently evaluating which transition approach to use and the full impact this ASU will have on our future financial statements.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	'
	The following information is necessary to calculate earnings per share for the periods presented:
	Year ended June 30,	2014			2013			2012
	Net loss, as reported	$	-2,805,913		$	-1,256,773		$	-424,426
	Weighted average common shares outstanding		8,027,147			8,070,645			8,124,386
	Effect of dilutive stock options		-			-			-
	Weighted average diluted common shares outstanding		8,027,147			8,070,645			8,124,386
	Net loss per common share
	Basic	$	-0.35		$	-0.16		$	-0.05
	Diluted	$	-0.35		$	-0.16		$	-0.05
	Employee stock options excluded from computation of diluted income per share amounts because their effect would be anti-dilutive		-			-			3,806
Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]	'
	The following table summarizes the weighted average assumptions utilized in the Black-Scholes option pricing model for options granted during the fiscal years ended June 30, 2014, 2013 and 2012.
		2014				2013				2012
	Weighted-average fair value	$	1.04			$	1.15			$	1.6
	Weighted-average volatility		45	%			46	%			46	%
	Weighted-average expected life (in years)		6				6				6
	Weighted-average risk-free interest rate		1.68	%			0.93	%			1.67	%
	Dividend yield		0	%			0	%			0	%

Lease_Commitments_Tables

Lease Commitments (Tables)	12 Months Ended
	Jun. 30, 2014
Leases [Abstract]	'
Operating Leases of Lessee Disclosure [Table Text Block]	'
	The Company leases certain of its equipment under non-cancelable operating lease agreements. Minimum lease payments under operating leases at June 30, 2014 are as follows:
	Fiscal Year	Operating
		Leases
	2015		82,021
	2016		60,575
	2017		53,246
	2018		50,630
	2019		3,934
	Total minimum lease payments	$	250,406

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Jun. 30, 2014
Income Tax Disclosure [Abstract]	'
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	'
	The provision for (benefit from) income taxes consists of the following:
		2014		2013		2012
	Current:
	Federal	$	-	$	-	$	-
	State		12,933		17,661		11,581
	Total current		12,933		17,661		11,581
	Deferred:
	Federal		-1,050,750		-698,712		-252,778
	State		-102,199		-58,987		-4,723
	Valuation Allowance		800,203		-		-
	Total deferred		-352,746		-757,699		-257,501
		$	-339,813	$	-740,038	$	-245,920
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	'
	A reconciliation of income taxes, with the amounts computed at the statutory federal rate is as follows:
		2014		2013		2012
	Computed tax at federal statutory rate	$	-1,069,547	$	-678,916	$	-227,917
	State income taxes, net of federal tax (benefit) provision		-62,712		-32,502		-4,982
	Non deductible expenses		18,141		20,162		17,572
	Federal research credit		-15,328		-43,095		-31,507
	Other, net		-10,570		-5,687		914
	Valuation Allowance		800,203		-		-
	Total	$	-339,813	$	-740,038	$	-245,920
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	'
	The deferred tax assets and deferred tax liabilities recorded on the balance sheet as of June 30, 2014 and 2013 are as follows:
		2014				2013
		Deferred Tax		Deferred Tax		Deferred Tax		Deferred Tax
		Assets		Liabilities		Assets		Liabilities
	Current:
	Bad debts	$	40,000	$	—	$	40,000	$	—
	Prepaid expenses		—		22,971		—		16,646
	Accrued liabilities		304,747		—		335,744		—
	Inventory		—		1,152,722		—		1,204,637
			344,747		1,175,693		375,744		1,221,283
	Non Current:
	Depreciation		—		535,510		—		479,840
	Net operating loss and credit carryforwards		2,987,082		—		1,771,164		—
	Intangible assets		1,306		—		143		—
	Accrued pension liability		29,700		—		32,840		—
	Stock options		363,385		—		368,941		—
	Other		—		49,327		—		25,549
			3,381,473		584,837		2,173,088		505,389
	Valuation Allowance		-800,203		—		—		—
	Total deferred taxes	$	2,926,017	$	1,760,530	$	2,548,832	$	1,726,672

Employee_Retirement_Benefits_T

Employee Retirement Benefits (Tables)

12 Months Ended

Jun. 30, 2014

Compensation and Retirement Disclosure [Abstract]

'

Schedule of Costs of Retirement Plans [Table Text Block]

'

PPA Zone Status

Contributions by the Company

FIP/RP

Status

Pending/

Surcharge

Expiration

Pension Trust Fund

EIN/PN

2013

2012

Implemented

2014

2013

2012

Imposed

Date of CBA

District No. 9 International

51-0138317/001

Green

Green

Association of

12/31/12

12/31/11

Implemented

$

293,377

$

309,373

$

331,154

No

5/31/15

Machinist and

Aerospace Workers

Pension Plan

Stock_Based_Compensation_Table

Stock Based Compensation (Tables)	12 Months Ended
	Jun. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
	A summary of stock option transactions in fiscal 2012, 2013 and 2014, respectively, pursuant to the Employee Plans and the Directors Plans is as follows:
							Weighted
							Average
				Weighted			Remaining		Aggregate
				Average			Contractual		Intrinsic
		Shares		Exercise Price			Term (years)		Value
	30-Jun-11		448,000	$	4.38
	Options Granted		51,000	$	3.51
	Options Exercised		0	$	0
	Options Forfeited or Expired		-31,000	$	3.4
	30-Jun-12		468,000	$	4.35			4.1	$	330
	30-Jun-12		468,000	$	4.35
	Options Granted		6,000	$	2.59
	Options Exercised		0	$	0
	Options Forfeited or Expired		-1,500	$	2.9
	30-Jun-13		472,500	$	4.34			3.2	$	960
	30-Jun-13		472,500	$	4.34
	Options Granted		6,000	$	2.31
	Options Exercised		0	$	0
	Options Forfeited or Expired		-12,500	$	4.74
	30-Jun-14		466,000	$	4.3			2.3	$	660
	Exercisable at June 30, 2014		460,000	$	4.32			2.2	$	-
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	'
	The following table provides additional information for options outstanding and exercisable at June 30, 2014:
	Options Outstanding
	Range of Exercise Prices		Number	Weighted Average		Weighted Average
				Remaining Life		Exercise Price
	2.31 - 4.24		69,000	7.2 years		$	3.37
	4.25 - 4.25		320,000	1.2 years		$	4.25
	4.26 - 6.84		77,000	2.7 years		$	5.33
	$2.31 - 6.84		466,000	2.3 years		$	4.3
	Options Exercisable
	Range of Exercise Prices		Number	Weighted Average
				Exercise Price
	2.31 - 4.24		63,000	$	3.47
	4.25 - 4.25		320,000	$	4.25
	4.26 - 6.84		77,000	$	5.33
	$2.31 - 6.84		460,000	$	4.32

Supplemental_Balance_Sheet_Inf1

Supplemental Balance Sheet Information (Tables)	12 Months Ended
	Jun. 30, 2014
Supplemental Balance Sheet Information [Abstract]	'
Condensed Balance Sheet [Table Text Block]	'
		June 30,
		2014			2013
	Inventories
	Work in progress	$	616,474		$	663,100
	Component parts		7,605,543			7,530,506
	Finished goods		2,617,799			2,457,337
	Reserve for obsolete and excess inventory		-1,433,718			-1,312,600
		$	9,406,098		$	9,338,343
		Estimated
		Useful Life
		(years)
	Property, plant and equipment
	Machinery and equipment	10-Mar		$	14,609,438		$	14,306,930
	Buildings	28-35			13,048,090			12,912,094
	Land and land improvements	7-May			934,216			934,216
	Total property, plant and equipment at cost				28,591,744			28,153,240
	Less accumulated depreciation and amortization				-19,656,143			-18,430,896
				$	8,935,601		$	9,722,344
	Depreciation expense was  approximately $1.2 million, $1.2 million, and $1.3 million for the fiscal years ended June 30, 2014, 2013 and 2012, respectively.
	Other accrued liabilities
	Accrued compensation expense	$	1,064,354		$	1,187,224
	Customer deposits		252,496			359,597
	Other		307,336			314,420
		$	1,624,186		$	1,861,241

Segment_Information_Tables

Segment Information (Tables)	12 Months Ended
	Jun. 30, 2014
Segment Reporting [Abstract]	'
Schedule Of Revenue Information By Product [Table Text Block]	'
	Sales by region, and by product, are as follows:
	Sales by Region
		2014		2013		2012
	Domestic United States	$	27,214,060	$	29,180,042	$	33,816,317
	Europe		858,735		1,421,347		1,510,197
	Canada		758,392		673,011		603,530
	Latin America		4,291,530		4,113,201		4,883,288
	Middle East		1,214,389		1,228,318		925,658
	Far East		2,011,714		1,841,771		1,594,172
	Other International		21,796		94,084		112,459
		$	36,370,616	$	38,551,774	$	43,445,621
	Sales by Product
		2014		2013		2012
	Respiratory care products	$	9,688,486	$	8,944,319	$	10,082,450
	Medical gas equipment		19,425,522		21,870,840		24,803,614
	Emergency medical products		7,256,608		7,736,615		8,559,557
		$	36,370,616	$	38,551,774	$	43,445,621

Quarterly_Financial_Data_unaud1

Quarterly Financial Data (unaudited) (Tables)	12 Months Ended
	Jun. 30, 2014
Quarterly Financial Information Disclosure [Abstract]	'
Schedule of Quarterly Financial Information [Table Text Block]	'
	Summarized quarterly financial data for fiscal 2014 and 2013 appears below (all amounts in thousands except per share amounts):
		June 30,		March 31,		Dec. 31,		Sept. 30,		June 30,		March 31,		Dec. 31,		Sept. 30,
	Three months ended,	2014		2014		2013		2013		2013		2013		2012		2012
	Net sales	$	9,798	$	9,116	$	8,749	$	8,708	$	10,133	$	9,210	$	9,921	$	9,287
	Gross profit		1,861		1,748		1,944		1,761		2,478		1,680		2,106		1,979
	Loss from operations		-395		-960		-892		-862		-122		-960		-751		-660
	Net loss		-347		-969		-899		-591		-98		-279		-469		-411
	Basic loss per share		-0.04		-0.12		-0.11		-0.07		-0.01		-0.03		-0.06		-0.05
	Diluted loss per share		-0.04		-0.12		-0.11		-0.07		-0.01		-0.03		-0.06		-0.05

Baralyme_Agreement_Tables

Baralyme Agreement (Tables)	12 Months Ended
	Jun. 30, 2014
Deferred Revenue Disclosure [Abstract]	'
Deferred Revenue, by Arrangement, Disclosure [Table Text Block]	'
	A reconciliation of deferred revenue resulting from the agreement with Abbott, with the amounts received under the agreement, and amounts recognized as net sales is as follows:
		Twelve Months ended
		June 30,
		2014		2013
	Beginning balance	$	-	$	114,700
	Revenue recognized as net sales		-		-114,700
			-		0
	Less - Current portion of deferred revenue		-		0
		$	-	$	0

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Details) (USD $)	3 Months Ended								12 Months Ended
	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Schedule Of Significant Accounting Policies [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Net loss, as reported	($347)	($969)	($899)	($591)	($98)	($279)	($469)	($411)	($2,805,913)	($1,256,773)	($424,426)
Weighted average common shares outstanding (in shares)	'	'	'	'	'	'	'	'	8,027,147	8,070,645	8,124,386
Effect of dilutive stock options (in shares)	'	'	'	'	'	'	'	'	0	0	0
Weighted average diluted common shares outstanding (in shares)	'	'	'	'	'	'	'	'	8,027,147	8,070,645	8,124,386
Net loss per common share	'	'	'	'	'	'	'	'	'	'	'
Basic (in dollars per share)	($0.04)	($0.12)	($0.11)	($0.07)	($0.01)	($0.03)	($0.06)	($0.05)	($0.35)	($0.16)	($0.05)
Diluted (in dollars per share)	($0.04)	($0.12)	($0.11)	($0.07)	($0.01)	($0.03)	($0.06)	($0.05)	($0.35)	($0.16)	($0.05)
Employee stock options excluded from computation of diluted income per share amounts because their effect would be anti-dilutive	'	'	'	'	'	'	'	'	0	0	3,806

Summary_of_Significant_Account4

Summary of Significant Accounting Policies (Details 1) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Schedule Of Significant Accounting Policies [Line Items]	'	'	'
Weighted-average fair value	$1.04	$1.15	$1.60
Weighted-average volatility	45.00%	46.00%	46.00%
Weighted-average expected life (in years)	'6 years	'6 years	'6 years
Weighted-average risk-free interest rate	1.68%	0.93%	1.67%
Dividend yield	0.00%	0.00%	0.00%

Summary_of_Significant_Account5

Summary of Significant Accounting Policies (Details Textual) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Schedule Of Significant Accounting Policies [Line Items]	'	'	'
Revenue Recognition Multiple Deliverable Arrangements Determination Of Liability Amount	$130,000	$130,000	'
Advertising Expense	17,904	46,691	46,278
FIFO Inventory Amount	2,473,787	2,343,788	'
Decreases In Cost Of Goods Sold	0	171,918	164,645
Inventory Valuation Reserves	1,433,718	1,312,600	'
Entity Number of Employees	243	'	'
Collective Bargaining Period Expiry Date	31-May-15	'	'
Health Care Insurance Accrued Liabilities	150,000	200,000	'
Gain Contingency, Description	'Benefits from tax positions are measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon settlement.	'	'
Research and Development Expense	657,356	937,598	948,213
Weighted Average Number Of Shares Outstanding, Basic	8,027,147	8,070,645	8,124,386
Weighted Average Number Of Shares Outstanding, Diluted	8,027,147	8,070,645	8,124,386
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	0	3,806
Allocated Share-based Compensation Expense	10,000	44,000	44,000
Unrecognized Shared Based Compensation	2,000	'	'
Employee Service Share-based Compensation, Tax Benefit from Compensation Expense	4,000	18,000	18,000
Warranty Service [Member]	'	'	'
Schedule Of Significant Accounting Policies [Line Items]	'	'	'
Revenue Recognition	$113,209	$150,944	$152,625
Collective Bargaining Agreement [Member]	'	'	'
Schedule Of Significant Accounting Policies [Line Items]	'	'	'
Entity Number of Employees	148	'	'
Maximum [Member]	'	'	'
Schedule Of Significant Accounting Policies [Line Items]	'	'	'
Property, Plant and Equipment, Useful Life	'35 years	'	'
Minimum [Member]	'	'	'
Schedule Of Significant Accounting Policies [Line Items]	'	'	'
Property, Plant and Equipment, Useful Life	'3 years	'	'

Financing_Details_Textual

Financing (Details Textual) (USD $)	12 Months Ended
	Jun. 30, 2014	Nov. 17, 2009
Debt Instrument [Line Items]	'	'
Line Of Credit Facility, Maximum Borrowing Capacity	'	$5,000,000
Line of Credit Facility, Current Borrowing Capacity	$5,000,000	'
Debt Instrument, Maturity Date	11-Nov-14	'
Debt Instrument, Interest Rate, Stated Percentage Rate Range, Minimum	3.50%	'
Debt Instrument, Interest Rate, Stated Percentage	4.00%	'
Debt Instrument, Basis Spread on Variable Rate	0.15%	'

Lease_Commitments_Details

Lease Commitments (Details) (USD $)	Jun. 30, 2014
Operating Leased Assets [Line Items]	'
2015	$82,021
2016	60,575
2017	53,246
2018	50,630
2019	3,934
Total minimum lease payments	$250,406

Lease_Commitments_Details_Text

Lease Commitments (Details Textual) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Operating Leased Assets [Line Items]	'	'	'
Operating Leases, Rent Expense, Net	$236,826	$255,517	$238,486

Income_Taxes_Details

Income Taxes (Details) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Current:	'	'	'
Federal	$0	$0	$0
State	12,933	17,661	11,581
Total current	12,933	17,661	11,581
Deferred:	'	'	'
Federal	-1,050,750	-698,712	-252,778
State	-102,199	-58,987	-4,723
Valuation Allowance	800,203	0	0
Total deferred	-352,746	-757,699	-257,501
Income Tax Expense (Benefit)	($339,813)	($740,038)	($245,920)

Income_Taxes_Details_1

Income Taxes (Details 1) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Schedule Of Income Tax Disclosure [Line Items]	'	'	'
Computed tax at federal statutory rate	($1,069,547)	($678,916)	($227,917)
State income taxes, net of federal tax (benefit) provision	-62,712	-32,502	-4,982
Non deductible expenses	18,141	20,162	17,572
Federal research credit	-15,328	-43,095	-31,507
Other, net	-10,570	-5,687	914
Valuation Allowance	800,203	0	0
Income Tax Expense (Benefit)	($339,813)	($740,038)	($245,920)

Income_Taxes_Details_2

Income Taxes (Details 2) (USD $)	Jun. 30, 2014	Jun. 30, 2013
Schedule Of Income Tax Disclosure [Line Items]	'	'
Deferred Tax Assets, Gross, Current	$344,747	$375,744
Deferred Tax Liabilities, Gross, Current	1,175,693	1,221,283
Deferred Tax Assets, Gross, Noncurrent	3,381,473	2,173,088
Deferred Tax Liabilities, Net, Noncurrent	584,837	505,389
Total Deferred Tax Assets	2,926,017	2,548,832
Total Deferred Tax Liabilities	1,760,530	1,726,672
Deferred Tax Liabilities Current [Member]	'	'
Schedule Of Income Tax Disclosure [Line Items]	'	'
Bad debts	0	0
Prepaid expenses	22,971	16,646
Accrued liabilities	0	0
Inventory	1,152,722	1,204,637
Deferred Tax Liabilities Non Current [Member]	'	'
Schedule Of Income Tax Disclosure [Line Items]	'	'
Depreciation	535,510	479,840
Net operating loss and credit carryforwards	0	0
Intangible assets	0	0
Accrued pension liability	0	0
Stock options	0	0
Other	49,327	25,549
Valuation Allowance	0	0
Deferred Tax Asset Current [Member]	'	'
Schedule Of Income Tax Disclosure [Line Items]	'	'
Bad debts	40,000	40,000
Prepaid expenses	0	0
Accrued liabilities	304,747	335,744
Inventory	0	0
Deferred Tax Asset Non Current [Member]	'	'
Schedule Of Income Tax Disclosure [Line Items]	'	'
Depreciation	0	0
Net operating loss and credit carryforwards	2,987,082	1,771,164
Intangible assets	1,306	143
Accrued pension liability	29,700	32,840
Stock options	363,385	368,941
Other	0	0
Valuation Allowance	($800,203)	$0

Income_Taxes_Details_Textual

Income Taxes (Details Textual) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014
Schedule Of Income Tax Disclosure [Line Items]	'
Deferred Tax Assets, Operating Loss Carryforwards, Domestic	7.6
Deferred Tax Assets, Operating Loss Carryforwards, State and Local	6.6
Minimum [Member] | Domestic Tax Authority [Member]	'
Schedule Of Income Tax Disclosure [Line Items]	'
Operating Loss Carryforward Expiration Date	'2031
Minimum [Member] | State and Local Jurisdiction [Member]	'
Schedule Of Income Tax Disclosure [Line Items]	'
Operating Loss Carryforward Expiration Date	'2029
Maximum [Member] | Domestic Tax Authority [Member]	'
Schedule Of Income Tax Disclosure [Line Items]	'
Operating Loss Carryforward Expiration Date	'2034
Maximum [Member] | State and Local Jurisdiction [Member]	'
Schedule Of Income Tax Disclosure [Line Items]	'
Operating Loss Carryforward Expiration Date	'2034

Employee_Retirement_Benefits_D

Employee Retirement Benefits (Details) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Schedule Of Employee Retirement Benefits [Line Items]	'	'	'
Contributions by the Company	$293,377	$309,373	$331,154
Expiration Date	31-May-15	'	'
Multiemployer Plans, Surcharge	'No	'	'

Employee_Retirement_Benefits_D1

Employee Retirement Benefits (Details Texual) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Schedule Of Employee Retirement Benefits [Line Items]	'	'	'
Defined Benefit Plan, Contributions by Employer	$277,374	$278,212	$247,576
Percentage Of Eligible Salaried Employees Annual Income	2.00%	'	'
Percentage Of Annual Income To Plan	25.00%	'	'
Percentage Of Employee Deferrals	8.00%	'	'

Stock_Based_Compensation_Detai

Stock Based Compensation (Details) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Schedule Of Share Based Compensation Stock Options Activity [Line Items]	'	'	'
Beginning Balance, Shares	472,500	468,000	448,000
Beginning Balance, Weighted Average Exercise Price	$4.34	$4.35	$4.38
Options Granted, Shares	6,000	6,000	51,000
Options Granted, Weighted Average Exercise Price	$2.31	$2.59	$3.51
Options Exercised, Shares	0	0	0
Options Exercised, Weighted Average Exercise Price	$0	$0	$0
Options Forfeited or Expired, Shares	-12,500	-1,500	-31,000
Options Forfeited or Expired, Weighted Average Exercise Price	$4.74	$2.90	$3.40
Ending Balance, Shares	466,000	472,500	468,000
Ending Balance, Weighted Average Exercise Price	$4.30	$4.34	$4.35
Options, Weighted Average Remaining Contractual Terms (years)	'2 years 3 months 18 days	'3 years 2 months 12 days	'4 years 1 month 6 days
Options, Aggregated Intrinsic Value	$660	$960	$330
Exercisable, Shares	460,000	'	'
Exercisable, Weighted Average Exercise Price	$4.32	'	'
Exercisable, Weighted Average Remaining Contractual Terms (years)	'2 years 2 months 12 days	'	'
Exercisable, Aggregated Intrinsic Value	$0	'	'

Stock_Based_Compensation_Detai1

Stock Based Compensation (Details 1) (USD $)	12 Months Ended
	Jun. 30, 2014
2.31 - 4.24 Exercise Price [Member]	'
Schedule Of Share Based Compensation Stock Options Activity [Line Items]	'
Exercise Prices, Lower Range	$2.31
Exercise Prices, Upper range	$4.24
Options Outstanding, Numbers	69,000
Options Outstanding, Weighted Average Remaining Life	'7 years 2 months 12 days
Option Outstanding, Weighted Average Exercise Price	$3.37
Options Exercisable, Numbers	63,000
Options Exercisable, Weighted Average Exercise Price	$3.47
4.25 - 4.25 Exercise Price [Member]	'
Schedule Of Share Based Compensation Stock Options Activity [Line Items]	'
Exercise Prices, Lower Range	$4.25
Exercise Prices, Upper range	$4.25
Options Outstanding, Numbers	320,000
Options Outstanding, Weighted Average Remaining Life	'1 year 2 months 12 days
Option Outstanding, Weighted Average Exercise Price	$4.25
Options Exercisable, Numbers	320,000
Options Exercisable, Weighted Average Exercise Price	$4.25
4.26 - 6.84 Exercise Price [Member]	'
Schedule Of Share Based Compensation Stock Options Activity [Line Items]	'
Exercise Prices, Lower Range	$4.26
Exercise Prices, Upper range	$6.84
Options Outstanding, Numbers	77,000
Options Outstanding, Weighted Average Remaining Life	'2 years 8 months 12 days
Option Outstanding, Weighted Average Exercise Price	$5.33
Options Exercisable, Numbers	77,000
Options Exercisable, Weighted Average Exercise Price	$5.33
2.31 - 6.84 Exercise Price [Member]	'
Schedule Of Share Based Compensation Stock Options Activity [Line Items]	'
Exercise Prices, Lower Range	$2.31
Exercise Prices, Upper range	$6.84
Options Outstanding, Numbers	466,000
Options Outstanding, Weighted Average Remaining Life	'2 years 3 months 18 days
Option Outstanding, Weighted Average Exercise Price	$4.30
Options Exercisable, Numbers	460,000
Options Exercisable, Weighted Average Exercise Price	$4.32

Stock_Based_Compensation_Detai2

Stock Based Compensation (Details Textual)	12 Months Ended
	Jun. 30, 2014
Employee Plan [Member]	'
Schedule Of Share Based Compensation Stock Options Activity [Line Items]	'
Share-based Compensation Arrangement by Share-based Payment Award, Shares Purchased for Award	2,150,000
Director Plan [Member]	'
Schedule Of Share Based Compensation Stock Options Activity [Line Items]	'
Share-based Compensation Arrangement by Share-based Payment Award, Shares Purchased for Award	300,000

Supplemental_Balance_Sheet_Inf2

Supplemental Balance Sheet Information (Details) (USD $)

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Machinery and Equipment [Member]

Machinery and Equipment [Member]

Building [Member]

Building [Member]

Land and Land Improvements [Member]

Land and Land Improvements [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Minimum [Member]

Minimum [Member]

Minimum [Member]

Minimum [Member]

Machinery and Equipment [Member]

Building [Member]

Land and Land Improvements [Member]

Machinery and Equipment [Member]

Building [Member]

Land and Land Improvements [Member]

Schedule Of Supplemental Balance Sheet Information [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Inventories, Work in progress

$616,474

$663,100

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Inventories, Component parts

7,605,543

7,530,506

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Inventories, Finished goods

2,617,799

2,457,337

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Reserve for obsolete and excess inventory

-1,433,718

-1,312,600

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Inventory, Net

9,406,098

9,338,343

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total property, plant and equipment at cost

28,591,744

28,153,240

14,609,438

14,306,930

13,048,090

12,912,094

934,216

934,216

'

'

'

'

'

'

'

'

Less accumulated depreciation and amortization

-19,656,143

-18,430,896

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Property, plant and equipment, net

8,935,601

9,722,344

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Property, Plant and Equipment, Useful Life

'

'

'

'

'

'

'

'

'35 years

'10 years

'35 years

'7 years

'3 years

'3 years

'28 years

'5 years

Other accrued liabilities

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Accrued compensation expense

1,064,354

1,187,224

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Customer deposits

252,496

359,597

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Other

307,336

314,420

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Other accrued liabilities

$1,624,186

$1,861,241

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Supplemental_Balance_Sheet_Inf3

Supplemental Balance Sheet Information (Details Textual) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Schedule Of Supplemental Balance Sheet Information [Line Items]	'	'	'
Depreciation	$1.20	$1.20	$1.30

Demutualization_of_Product_Lia1

Demutualization of Product Liability Insurer (Details Textual) (USD $)	1 Months Ended
	Jan. 31, 2013
Demutualization of Product Liability Insurer [Line Items]	'
Demutualization by Insurance Entity, Securities Issued, Gross Cash Proceeds	$516,000

Commitments_and_Contingencies_

Commitments and Contingencies (Details Textual) (Niagara [Member], USD $)	0 Months Ended
	Mar. 14, 2014
Niagara [Member]	'
Commitments and Contingencies [Line Items]	'
Loss Contingency, Damages Sought, Value	$492,000

Segment_Information_Details

Segment Information (Details) (USD $)	3 Months Ended								12 Months Ended
	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Net sales	$9,798	$9,116	$8,749	$8,708	$10,133	$9,210	$9,921	$9,287	$36,370,616	$38,551,774	$43,445,621
Domestic United States [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	27,214,060	29,180,042	33,816,317
Europe [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	858,735	1,421,347	1,510,197
Canada [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	758,392	673,011	603,530
Latin America [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	4,291,530	4,113,201	4,883,288
Middle East [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	1,214,389	1,228,318	925,658
Far East [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	2,011,714	1,841,771	1,594,172
Other International [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	$21,796	$94,084	$112,459

Segment_Information_Details_1

Segment Information (Details 1) (USD $)	3 Months Ended								12 Months Ended
	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Net sales	$9,798	$9,116	$8,749	$8,708	$10,133	$9,210	$9,921	$9,287	$36,370,616	$38,551,774	$43,445,621
Respiratory care products [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	9,688,486	8,944,319	10,082,450
Medical gas equipment [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	19,425,522	21,870,840	24,803,614
Emergency medical products [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	$7,256,608	$7,736,615	$8,559,557

Quarterly_Financial_Data_unaud2

Quarterly Financial Data (unaudited) (Details) (USD $)	3 Months Ended								12 Months Ended
	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Schedule Of Quarterly Financial Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Net sales	$9,798	$9,116	$8,749	$8,708	$10,133	$9,210	$9,921	$9,287	$36,370,616	$38,551,774	$43,445,621
Gross profit	1,861	1,748	1,944	1,761	2,478	1,680	2,106	1,979	7,314,249	8,242,290	9,961,109
Loss from operations	-395	-960	-892	-862	-122	-960	-751	-660	-3,108,884	-2,493,516	-649,749
Net loss	($347)	($969)	($899)	($591)	($98)	($279)	($469)	($411)	($2,805,913)	($1,256,773)	($424,426)
Basic loss per share (in dollars per share)	($0.04)	($0.12)	($0.11)	($0.07)	($0.01)	($0.03)	($0.06)	($0.05)	($0.35)	($0.16)	($0.05)
Diluted loss per share (in dollars per share)	($0.04)	($0.12)	($0.11)	($0.07)	($0.01)	($0.03)	($0.06)	($0.05)	($0.35)	($0.16)	($0.05)

Baralyme_Agreement_Details

Baralyme Agreement (Details) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Deferred Revenue Arrangement [Line Items]	'	'	'
Beginning balance	$0	$114,700	'
Revenue recognized as net sales	0	-114,700	-688,200
Ending balance	0	0	114,700
Less - Current portion of deferred revenue	0	0	'
Noncurrent portion of deferred revenue	$0	$0	'

Baralyme_Agreement_Details_Tex

Baralyme Agreement (Details Textual) (USD $)	3 Months Ended	12 Months Ended			36 Months Ended
	Sep. 30, 2004	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2008
Deferred Revenue Arrangement [Line Items]	'	'	'	'	'
Abbott agreed to pay Allied	$5,250,000	'	'	'	'
Consideration Paid	1,530,000	'	'	'	'
Deferred Revenue Revenue Yet To Be Recognized	'	'	'	'	930,000
Deferred Revenue, Revenue Recognized	'	0	114,700	688,200	'
Deferred Revenue, Refund Payments	$600,000	'	'	'	'

Share_Repurchases_Details_Text

Share Repurchases (Details Textual) (USD $)	1 Months Ended
	Feb. 25, 2013	Nov. 21, 2012
Share Repurchases [Line Items]	'	'
Stock Repurchase Program, Number of Shares Authorized to be Repurchased	100,000	100,000
Stock Repurchased During Period, Shares	3,100	94,139
Stock Repurchased Price Per Share (in dollars per share)	$2.69	$2.54
Stock Repurchased During Period, Value	$8,408	$240,952